Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $2.1 million.

  • Zevra Therapeutics' Interest Expenses fell 1128.89% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year increase of 3906.65%. This contributed to the annual value of $7.4 million for FY2024, which is 38974.02% up from last year.
  • According to the latest figures from Q3 2025, Zevra Therapeutics' Interest Expenses is $2.1 million, which was down 1128.89% from $2.0 million recorded in Q2 2025.
  • Zevra Therapeutics' Interest Expenses' 5-year high stood at $2.3 million during Q3 2024, with a 5-year trough of $5000.0 in Q4 2021.
  • In the last 5 years, Zevra Therapeutics' Interest Expenses had a median value of $199000.0 in 2021 and averaged $812736.8.
  • As far as peak fluctuations go, Zevra Therapeutics' Interest Expenses tumbled by 9957.08% in 2021, and later soared by 354000.0% in 2023.
  • Zevra Therapeutics' Interest Expenses (Quarter) stood at $5000.0 in 2021, then soared by 3300.0% to $170000.0 in 2022, then surged by 344.71% to $756000.0 in 2023, then surged by 190.21% to $2.2 million in 2024, then fell by 6.52% to $2.1 million in 2025.
  • Its Interest Expenses was $2.1 million in Q3 2025, compared to $2.0 million in Q2 2025 and $2.0 million in Q1 2025.